{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-071392","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.461433+00:00","generated_at":"2026-05-17T21:35:31.542255+00:00","sec_items":["5.07"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Helix shareholders approve all proposals for business combination with BridgeBio Oncology Therapeutics","bullets":["Business Combination Proposal approved: 17.3M FOR, 2.1M AGAINST (82.55% quorum).","Domestication to Delaware, new charter and bylaws, name change to BridgeBio Oncology Therapeutics Inc. approved.","All 9 director nominees elected unanimously with 19.4M votes each; effective at closing.","2025 Stock Option and Incentive Plan and Employee Stock Purchase Plan both approved by shareholders."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-071392","json":"https://secwatch.observer/filing/0001213900-25-071392.json","markdown":"https://secwatch.observer/filing/0001213900-25-071392.md","text":"https://secwatch.observer/filing/0001213900-25-071392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025071392/0001213900-25-071392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025071392/ea0251413-8k425_helix2.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:35:31.542255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}